Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Assets (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Current Assets for 7 consecutive years, with $413.1 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 5.01% to $413.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $413.1 million through Dec 2025, down 5.01% year-over-year, with the annual reading at $413.1 million for FY2025, 5.01% down from the prior year.
  • Current Assets for Q4 2025 was $413.1 million at 4D Molecular Therapeutics, up from $312.4 million in the prior quarter.
  • The five-year high for Current Assets was $552.6 million in Q2 2024, with the low at $165.7 million in Q3 2021.
  • Average Current Assets over 5 years is $321.1 million, with a median of $299.9 million recorded in 2023.
  • The sharpest move saw Current Assets soared 158.69% in 2024, then plummeted 45.12% in 2025.
  • Over 5 years, Current Assets stood at $256.3 million in 2021, then dropped by 13.96% to $220.5 million in 2022, then surged by 34.5% to $296.6 million in 2023, then surged by 46.65% to $434.9 million in 2024, then decreased by 5.01% to $413.1 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $413.1 million, $312.4 million, and $303.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.